Vidox

Quick links to important sections

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Vidox

Property Description
Active ingredient Mupirocin (as Mupirocin Calcium)
Form Topical Ointment or Cream
Pharmacological class Antibiotic (Topical Antibacterial Agent)
General purpose Localized bacterial control
Origin Semi-synthetic (derived from Pseudomonas fluorescens)

Vidox is a specific topical pharmaceutical preparation containing the active ingredient Mupirocin (formulated as Mupirocin Calcium), classified as an RNA Synthetase Inhibitor Antibacterial. It is an antibiotic designed exclusively for application to the skin, establishing it as a specialized, single-ingredient topical antibacterial agent.

The active component, Mupirocin, is a semi-synthetic compound produced by fermentation using the organism Pseudomonas fluorescens. This distinct origin separates Mupirocin from the chemical structures of most other established systemic and local antibiotic classes, a differentiation that allows it to maintain specialized activity. The drug's unique mechanism of action is clinically recognized for its efficacy in providing localized antibacterial support against susceptible Gram-positive bacteria, an activity supported by pharmacological studies.

What is the Composition and General Purpose of Vidox?

Vidox is a specialized topical preparation that is primarily available as an ointment or a cream, formulated for dermal application. The Mupirocin Calcium is typically incorporated into an inert vehicle base, such as a polyethylene glycol base for the ointment, ensuring the drug's activity is highly localized to the surface of the skin. Vidox is often encountered in scenarios requiring focused antibacterial action for common skin surface issues.

The general purpose of this medicine is to provide potent, targeted antibacterial support. Its fundamental biological action involves the selective and reversible binding to the bacterial enzyme isoleucyl-tRNA synthetase, which is essential for the creation of new bacterial proteins. By blocking this vital process, the drug effectively halts bacterial growth and multiplication, defining its general benefit as the localized control and clearance of susceptible microorganisms from the surface of the skin. This formulation ensures that the drug's action is concentrated where bacterial presence is an issue, maximizing local effect while minimizing systemic exposure.

Regulatory References

  1. National Institutes of Health (NIH)
  2. NIH Study

What side effects are possible with Vidox?

Possible Side Effects and Safety Information

Official regulatory documentation structures the safety profile of topical Mupirocin (Vidox) by classifying adverse reactions based on frequency and affected system-organ classes. The majority of reported effects are localized reactions to the application site.

Adverse Reactions by Classification

The most frequently reported effects are classified as Common and typically involve the skin and subcutaneous tissues. These include localized burning, stinging, pain, itching (pruritus), and erythema (redness). Some systemic effects, such as headache and nausea, are also commonly documented in regulatory labeling.

Reactions are classified as Very Rare based on post-marketing surveillance when they are severe and systemic. These serious reactions include anaphylaxis, angioedema, and generalized urticaria (hives), which fall under Immune System Disorders.

Specific Safety Considerations

The official label requires documentation of two key, administration-agnostic safety points:

  1. Risk of C. difficile: As with nearly all antibacterial agents, including those applied topically, the risk of Clostridium difficile-Associated Diarrhea (CDAD) is noted. This can occur during or even several weeks after the use of the medicine.
  2. Excipient-Related Restriction: The ointment formulation contains a polyethylene glycol (PEG) base. Regulatory documents explicitly state that this ointment should not be used on large areas of open or damaged skin in patients with moderate or severe renal impairment due to the potential absorption and renal excretion of the PEG base.

Prolonged use of this preparation may also lead to the overgrowth of non-susceptible organisms, which is a key duration-related safety pattern noted in official texts.

Overdose and Emergency Response

Vidox Overdose and When to Seek Help

Information regarding Vidox overdose is strictly based on official government regulatory documents. An overdose of Vidox is potentially serious and requires immediate medical intervention.

Documented Overdose Manifestations

Official labeling describes the following clinical signs associated with Vidox overdose:

  • Central Nervous System (CNS) Depression: Manifestations may include excessive sedation, stupor, or progression to coma.
  • Respiratory Compromise: Symptoms ranging from shallow, depressed respiration to potentially life-threatening respiratory arrest.
  • Cardiovascular Instability: Severe hypotension (low blood pressure) and changes in heart rate.

Mandatory Urgent Action

If a Vidox overdose is suspected or confirmed, immediate medical attention is required.

Required Action Description (as per regulatory documents)
Emergency Contact Contact Poison Control or emergency medical services immediately.
Medical Care Transport the individual to the nearest hospital emergency department without delay.

Overdose management is typically supportive, focusing on maintaining vital functions, securing the airway, and ensuring adequate ventilation. Continuous monitoring of the patient's neurological status and cardiorespiratory function is essential due to the risk of delayed or recurring effects. Specific supportive measures, such as the use of an antidote or decontamination procedures, are determined by the treating physician based on the patient's clinical state and official treatment guidelines.

Therapeutic Uses of Vidox

What Vidox Treats: Main Uses and Benefits

The therapeutic application of Vidox (Mupirocin topical) is applied in addressing localized bacterial control to manage acute skin infections and their associated symptomatic burden. Its core therapeutic use is consistent with established therapeutic standards for Mupirocin.


Resolution of Primary and Secondary Skin Infections

Vidox is commonly used across conditions characterized by periods of heightened symptoms such as impetigo and certain forms of folliculitis and furuncles. The medication is also considered relevant when supportive symptom management is appropriate for minor traumatic skin injuries (cuts, scrapes) or chronic skin conditions, like eczema, that develop a secondary bacterial component.

“Vidox plays a role in managing symptoms marked by purulent discharge and supports general well-being during symptomatic phases when skin lesions are affected by localized bacterial growth.”

The key benefit is that it supports the patient during difficult episodes by easing distress associated with these contagious lesions. By applying antibacterial control, the medication helps ease the localized pain, tenderness, and inflammation that accompany active infection, contributing to easing the overall symptom load during acute, disruptive skin manifestations.


Quick Fact: Relief for Crusting Sores

Vidox is used to help address symptom clusters like crusting sores, pustules, and acute localized redness, assisting with maintaining functional stability by supporting the management of the underlying lesion.

Eligibility and Restrictions for Use

Official Eligibility Rules for Vidox

The official regulatory profile for Vidox (Mupirocin topical) establishes clear eligibility rules that define permissible use, absolute prohibitions, and conditional restrictions.

Absolute Contraindications

Use is strictly contraindicated if there is a known history of hypersensitivity to the active ingredient, mupirocin, or to any of the product's excipients. Vidox is approved only for external dermal application and must not be used for ophthalmic (eye) purposes or at central intravenous catheter sites.

Age-Related Eligibility

Vidox is typically established for use in pediatric patients aged 2 months and older for approved indications, while use in infants under 2 months of age is not established by regulators.

Conditional and Restricted Use

Due to the presence of polyethylene glycol in the ointment base, the medicine is not recommended for patients with moderate to severe renal impairment. Application to large open wounds or extensive areas of skin is also restricted to limit systemic absorption.

For pregnant and breastfeeding individuals, use is conditional: it should only occur if clearly needed, and the medicine must be thoroughly removed from the breast area prior to nursing.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The official regulatory profile for Mupirocin topical (Vidox) indicates a low potential for systemic drug-drug interactions. Due to minimal systemic absorption, governmental regulatory documents typically state that no systemic drug interactions have been identified.

Interaction-Related Restrictions

Interactions are defined by specific constraints related to the product's formulation and its use with other topical agents:

  • Co-administration Restriction: Vidox must not be mixed or applied concurrently with any other lotions, creams, or ointments. This restriction is based on the physicochemical incompatibility of the products, as mixing can cause dilution which may reduce the antibacterial activity and potentially affect stability.

  • Excipient-Related Risk (Ointment Formulation): The polyethylene glycol base in the ointment formulation introduces a population-specific risk. This formulation should not be used where large quantities of the base might be absorbed (e.g., on large open wounds or damaged skin) in patients with moderate or severe renal impairment. This constraint relates to the risk of polyethylene glycol accumulation and subsequent toxicity due to impaired renal excretion.

  • Food, Alcohol, and Supplements: No specific interactions with food, alcohol, or herbal products are documented in official regulatory sources.

Mechanism of Action

Targeted Inhibition of Bacterial Protein Synthesis

Vidox's mechanism of action is characterized by specific targeting, leading to a mechanism of localized antibacterial action. The drug acts by focusing on a single, essential biological target: bacterial Isoleucyl-tRNA Synthetase (IleRS). By competitively inhibiting this enzyme, the drug blocks the first critical step in building bacterial proteins. This action establishes a block on microbial life processes by eliminating the bacterium's capacity to synthesize the proteins necessary for growth and replication.

Concentration-Dependent Cellular Shutdown

The mechanism operates within pathways involving rapid intracellular depletion of key building blocks. Binding to IleRS swiftly depletes the cellular pool of charged isoleucyl-tRNA, immediately arresting protein elongation. The high local concentrations achieved on the skin surface push this initial growth-inhibiting effect into a lethal bactericidal cascade, resulting in the localized elimination of the target pathogen. The mechanism is constrained by a lack of efficacy against certain pathogen types that possess impervious cell walls and is nullified by acquired genetic modifications to the target enzyme.

Dosage and Administration Information

How to Use Vidox: Official Administration Guidelines

Vidox (Mupirocin topical) is designated for topical use only and its administration is governed by established labeling principles. These instructions define the proper application, scheduling, and duration according to official guidelines.

Administration Protocol

The standard protocol requires applying the medication directly to the skin, following a precise schedule:

Feature Official Requirement
Route of Administration Topical (Cutaneous Use Only). Not for eyes, nose, or ingestion.
Dosing Schedule Apply a small amount or thin layer of the 2% formulation to cover the affected area.
Frequency Three Times Daily (TID).
Duration For a course of up to 10 days.

Procedural and Time Constraints

Use of Vidox is time-bound, with specific requirements for monitoring and handling:

  • Treatment Duration: The full treatment should not exceed 10 days. Official guidance requires that if no clinical response is observed within 3 to 5 days, the patient's condition must be re-evaluated.
  • Administration Conditions: The treated area may be covered with a sterile gauze dressing if desired. The product must not be mixed with any other preparation, as this can risk reducing the antibacterial activity.
  • Special Constraints: Contact with the eyes must be avoided. The formulation is also restricted from use in conjunction with intravenous cannulae or at central venous sites.

Population-Specific Rules

While dosing remains consistent for adults, specific minimum age limits apply for children:

  • Ointment: Approved for use in children 2 months of age and older.
  • Cream: Approved for use in children 3 months of age and older.

These instructions define the standardized, label-based approach for the administration of Vidox.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Vidox

Evidence for Use in Impetigo

The research base for Vidox (Mupirocin topical) in impetigo includes short-term Randomized Controlled Trials (RCTs). These studies were conducted to examine Vidox by comparing it against an inactive formulation or against oral antibiotics, in both adults and children who had limited to moderate impetigo. Researchers measured two main factors: the resolution of skin lesions, crusting, and redness, and the rate at which the causative bacteria were eliminated.

Studies report patterns observed in outcomes related to skin lesion appearance and the measured levels of target bacteria when Vidox was applied compared to an inactive topical formulation. Some trials also described patterns in the evolution of lesions and bacteria when Vidox was studied against certain oral antibiotics for these localized infections. This evidence contributes to understanding symptom patterns and microbial responses over the defined treatment interval.

Evidence for Use in Secondarily Infected Traumatic Skin Lesions

Vidox was evaluated in short-term Randomized Controlled Trials (RCTs) exploring its application on minor skin injuries, such as cuts and scrapes, that had developed secondary bacterial infections. The studies evaluated outcomes related to infection signs and symptoms, alongside measurements of bacterial presence in both children and adults (from 3 months of age) with these defined traumatic lesions.

Trials reported measurements of outcomes related to clinical response following a 10-day treatment period. The findings described patterns related to the measured levels of bacteria when the Mupirocin cream formulation was applied. Comparative evidence against a broad array of other topical agents for this particular type of infected lesion is often lacking.

Key Limitations and Areas of Research Uncertainty

The short-term trials exploring symptom changes typically ended follow-up within 7 to 16 days. Long-term outcomes are not fully established; findings mainly describe how symptoms evolved during the study period. Evidence is limited regarding the use of Vidox for extensive or severe forms of bullous impetigo. Furthermore, the specificity of findings for isolated folliculitis and furuncles is uncertain, as research cohorts often contained various skin infections. The scientific community continues to explore the full implications of antimicrobial resistance related to topical antibiotic use, and this remains an area where data are still emerging.

Key Studies & References

  1. Mupirocin for the treatment of impetigo in children (systematic review)

Frequently Asked Questions (FAQ)

Common questions about Vidox (FAQ)

Q: Is Vidox an antibiotic, or is it for something else?

A: According to official regulatory documents, Vidox is classified as an antibiotic that functions as an RNA Synthetase Inhibitor Antibacterial. It is designed exclusively for external application to the skin to control localized bacterial growth.


Q: How quickly should I expect Vidox to start working?

A: Official regulatory guidance states that a clinical response to treatment should be observed within a specific timeframe. If a noticeable improvement is not seen within 3 to 5 days of starting the treatment, the patient's condition may require re-evaluation by a healthcare provider.


Q: How long does Vidox stay in your system after you stop taking it?

A: Due to the topical nature of the medicine, only minimal amounts of the active ingredient are typically absorbed into the body through the skin. The small amount that may be absorbed is then rapidly broken down and excreted, primarily through the kidneys.


Q: Can Vidox be taken with common over-the-counter pain relievers?

A: Official documents state that no systemic drug interactions have been identified with Vidox. This is consistent with the fact that the topical formulation has minimal absorption into the bloodstream, where such interactions would typically occur.


Q: Does Vidox interact with vitamins or herbal supplements?

A: Official regulatory documents do not mention specific interactions with vitamins or herbal supplements. This lack of documented interaction is expected because Vidox is used on the skin and has minimal systemic absorption.


Q: Is it normal to feel a bit nauseous when first starting Vidox?

A: Nausea is listed in official documentation as a common adverse reaction that has been reported in clinical trials. If you experience nausea, it is a pattern documented in official reports.


Q: Is Vidox known to cause any long-term side effects?

A: Official documents state that long-term outcomes are not fully established because clinical trials were designed to be short-term. Official documents describe that prolonged use has been associated with the possibility of the overgrowth of non-susceptible organisms on the skin.


Q: Are there specific foods or drinks that should be avoided while using Vidox?

A: No specific interactions with food or alcohol are documented in official regulatory sources. The medicine is applied externally to the skin, which limits the potential for interactions that occur through the digestive system.


Q: What is the evidence regarding Vidox use during pregnancy?

A: The available human data on the use of Vidox during pregnancy are insufficient to establish a definitive drug-related risk. Animal studies, however, have not shown evidence of fetal harm when the drug is administered topically.


Q: Does Vidox cause weight gain or loss?

A: Official regulatory documents classifying the adverse reaction profile for Vidox do not list weight gain or weight loss as a common or frequently reported effect.


Q: Can Vidox affect my mood or cause anxiety?

A: Adverse reaction reports available in official regulatory documentation do not list effects on mood or anxiety among the commonly reported side effects.


Q: Is Vidox commonly used outside of the United States?

A: Official product characteristics and patient information leaflets for Mupirocin, the active ingredient in Vidox, are published by regulatory bodies in multiple countries and regions, including the United States, Europe, and Australia.


Q: Why do some people say they feel tired after taking Vidox?

A: Fatigue or tiredness are not listed as common or frequently reported adverse reactions in official regulatory documents describing the safety profile of the medicine.


Q: Is there a generic version of Vidox available?

A: Yes, the active ingredient in Vidox, mupirocin, is available in generic topical formulations that have been approved by regulatory agencies.


Q: What is the difference between Vidox and [Name of a common competitor drug]?

A: Vidox (Mupirocin) is classified as an RNA Synthetase Inhibitor Antibacterial. It has a unique mechanism of action that differs from the chemical structures of most other established antibiotic classes used for topical infections.


Q: Does Vidox have a known risk of causing dependence?

A: Official regulatory documents do not list dependence, abuse, or withdrawal as a known risk associated with the use of Vidox.


Q: Is Vidox safe to use for older adults (seniors)?

A: Clinical trials comparing older adult patients (over 65 years) to younger patients showed no overall difference in the efficacy or safety profile of the cream formulation.


Q: Can men and women take the same dose of Vidox?

A: The official dosage and administration instructions for Vidox apply consistently to all adult patients, regardless of gender.


Q: Is Vidox a controlled substance?

A: Vidox is classified as an antibiotic. It is not designated as a controlled substance in official federal regulatory schedules.


Q: Can Vidox make me feel dizzy or affect my ability to drive?

A: Official patient information states that it is unlikely to affect the ability to drive or operate machinery. Dizziness has been reported as an adverse effect of undifferentiated frequency.


Q: Is Vidox similar to a steroid?

A: Vidox is classified as an antibiotic that functions as an RNA Synthetase Inhibitor. It does not belong to the pharmacological class of medicines known as steroids.


Q: What are the main risks associated with stopping Vidox suddenly?

A: Official guidance emphasizes that the full course of treatment must be completed even if symptoms resolve earlier. Discontinuing before the full course is completed is officially associated with the possibility of the underlying bacterial infection returning.


Q: Is Vidox a new drug, or has it been around for a while?

A: The active ingredient in Vidox, mupirocin, has been available in topical formulations and approved by regulatory bodies for several decades, indicating a well-established history.

How should Vidox be stored and disposed of?

The storage and disposal of Vidox (Mupirocin topical) must adhere strictly to official regulatory guidelines to maintain stability and prevent misuse.

Official Storage Conditions

Vidox must be stored at Controlled Room Temperature, typically 20^circ to 25 C (68^circ to 77 F). The product must be kept away from heat, moisture, and direct light, and it is explicitly stated that it must not be frozen.

For stability, the medicine must remain tightly closed in its original container and is prohibited from being mixed with other preparations. The product must be stored out of the sight and reach of children.

Disposal Instructions

Unused or expired Vidox must be discarded. Disposal should be done in accordance with local requirements for medicinal waste, and the product must not be thrown away via wastewater or regular household waste.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Vidox found in:

A-Z Index: